# Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Canonical URL: https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026--73653d45
Ticker: IMVT
Company: Immunovant
Source: Immunovant
Published: 2026-07-23 20:05 EST
Original Source URL: https://www.immunovant.com/investors/news-events/press-releases/detail/84/immunovanttoreport-financial-results-for
## Summary

DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial…...

## Article Body
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT ) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link . The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar . The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com .

Contacts:

Investors

Keyur Parekh

keyur.parekh@roivant.com

Media

Stephanie Lee

stephanie.lee@roivant.com

Source: Immunovant Inc. Released July 23, 2026
## Recent Company News
- 2026-07-23 20:05 EST — [Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-first-quarter-ended-june-30-2026--73653d45) — Source: Immunovant
- 2026-05-20 11:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026) — Source: Immunovant
- 2026-05-11 20:05 EST — [Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026](https://biopharmsignal.com/news/IMVT/immunovant-to-report-financial-results-for-the-fourth-quarter-and-fiscal-year-ended-march-31-2026-and-provide-business-update-on-wednesday-may-20-2026) — Source: Immunovant
- 2026-04-02 09:00 EST — [Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)](https://biopharmsignal.com/news/IMVT/immunovant-announces-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted) — Source: Immunovant
- 2026-02-06 12:00 EST — [Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025](https://biopharmsignal.com/news/IMVT/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-third-quarter-ended-december-31-2025) — Source: Immunovant
## Related News
- 2026-07-23 20:08 EST — MARKET — [STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides](https://biopharmsignal.com/news/MARKET/stat-in-win-for-rfk-jr-fda-advisory-panel-narrowly-votes-to-allow-compounding-of-56ccdc64)
- 2026-07-23 17:25 EST — MARKET — [U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite](https://biopharmsignal.com/news/MARKET/u-s-health-officials-are-investigating-a-new-outbreak-of-a-diarrhea-causing-para-9e98f2f3)
- 2026-07-23 16:33 EST — MARKET — [STAT+: European regulators take steps to bolster clinical trial transparency](https://biopharmsignal.com/news/MARKET/stat-european-regulators-take-steps-to-bolster-clinical-trial-transparency-73aade26)
- 2026-07-23 16:30 EST — BRLI — [OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026](https://biopharmsignal.com/news/BRLI/opko-health-to-report-second-quarter-2026-financial-results-on-july-27-2026-4b38e04c)
- 2026-07-23 16:23 EST — MARKET — [STAT+: Popular insulin product enters shortage as other pens leave market](https://biopharmsignal.com/news/MARKET/stat-popular-insulin-product-enters-shortage-as-other-pens-leave-market-c3a6a199)